Iovance Biotherapeutics Inc is a pioneering biotech firm focused on developing innovative cell therapies for cancer treatment. Specializing in autologous tumor infiltrating lymphocyte technology, it offers solutions like Amtagvi for metastatic melanoma and Proleukin for renal cell carcinoma. The company is also advancing treatments for various cancers, including lung and gynecological cancers, through strategic partnerships with leading research institutions and biopharmaceutical companies. Originally Lion Biotechnologies, it rebranded to Iovance in 2017 and operates from San Carlos, California.